IR LIBRARY

CEO Message

CEOメッセージ.JPG

Dear Shareholders,

Our mission, "A World without Blindness," has remained steadfast since our foundation. This mission encapsulates our unwavering commitment to research and development, product innovation, and our contributions to society from our inception to the current day. The year 2023 represented a significant milestone in our journey to realize this vision, originating from Japan. As we move into 2024, we anticipate an even more substantial progression toward our goal.

The development of emixustat hydrochloride presents promising prospects for future treatments. By offering a novel therapeutic option for Stargardt's disease--a condition yet to have a cure--we are poised to make a significant contribution to the elimination of blindness. Over the past year, we have also intensified our efforts within Japan to promote the adoption of Kubota Glass technology. As our unique innovation, Kubota Glass continues to exhibit potential for growth. Furthermore, our remote retinal monitoring solution, eyeMO, seeks to revolutionize the preservation of ocular health, particularly in regions where access to medical services is scarce.

Outlook and Goals for 2024

Accelerating Global Expansion: Our aim is to extend the reach of Kubota Glass to global markets, thereby playing a pivotal role in combating myopia worldwide. Additionally, through the advancement of partnerships for eyeMO, we intend to showcase the transformative power of telemedicine on a global stage.

Progress in Emixustat Hydrochloride Development: Capitalizing on the insights garnered in 2023, we will redouble our efforts to secure strategic partnerships. By utilizing the existing efficacy data, our goal is to navigate the early approval, conditional approval, and other regulatory frameworks across various countries and regions more effectively.

Expansion of Educational and Awareness Initiatives: We will enhance our efforts to spread awareness about myopia risks and preventive strategies, particularly focusing on younger audiences to foster the development of healthy visual habits. Our objective is to move beyond the resignation to myopia as an unavoidable condition, by implementing educational campaigns aimed at empowering individuals with effective preventive measures.

As we forge ahead, we remain dedicated to the advancement of pioneering pharmaceuticals and medical technologies, with the vision that an increasing number of individuals will experience the gift of clear vision. In 2024, we pledge to join forces with you in our relentless pursuit of a future without blindness.


Sincerely,


Ryo Kubota, MD, PhD
Chairman, President, and Chief Executive Officer (CEO)
Kubota Pharmaceutical Holdings Co., Ltd.
March 2024